

CSD/BSE&NSE/BM/2023-24

May 25, 2023

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 25, 2023, has taken on record and approved the attached Audited Standalone and Consolidated Financial Statements of the Company prepared under IND AS for the quarter and year ending 31st March, 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Auditors' Reports of the Statutory Auditors.

Further, we are enclosing herewith the following documents:

- 1) Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2023 along with Statement of Assets and Liabilities, Profit & Loss account and Cash Flow Statement.
- 2) Auditor's Reports on the financial results as mentioned above
- 3) Declaration in respect of Audit Reports with unmodified opinion and
- 4) Earnings Presentation of our company to investors

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 1:20 P.M.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**

K. Hanumantha Rao
Company Secretary

Encl: as above

Suven Pharmaceuticals Limited




SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor ,SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31,2023 & UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR QUARTER ENDED 31st MARCH ' 2023.

Rs. in Lakhs

PART - I		STANDALONE				
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended	
		31-03-2023	31-12-2022	31-03-2022	31-03-2023	31-03-2022
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	AUDITED
1	Income					
	Revenue from operations	36,438.99	34,848.90	36,384.72	1,33,007.98	1,32,022.21
	Other Income	1,075.46	1,251.05	13,439.58	4,455.20	18,778.80
	Total income	37,514.45	36,099.95	49,824.30	1,37,463.18	1,50,801.01
2	Expenses					
	a) Cost of materials consumed	8,956.75	13,516.42	13,027.81	42,136.24	45,945.64
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,087.68	(2,650.99)	(1,994.03)	(2,094.42)	(6,035.21)
	c) Manufacturing Expenses	3,899.88	4,599.26	4,434.34	17,087.35	17,318.86
	d) Employee benefits expense	2,289.99	2,726.37	3,112.20	10,084.31	10,048.39
	e) R & D expense	200.89	226.99	214.42	858.57	1,035.45
	f) Finance costs	228.95	137.94	218.87	539.17	623.10
	g) Depreciation and amortisation expenses	1,062.73	1,091.38	1,042.08	4,284.46	3,909.71
	h) Other Expenses	1,540.99	1,724.14	1,833.11	6,628.17	5,710.25
	Total expenses	20,267.86	21,371.51	21,888.80	79,523.85	78,556.19
3	Profit before exceptional items & Tax (1-2)	17,246.59	14,728.44	27,935.50	57,939.33	72,244.82
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax (3-4)	17,246.59	14,728.44	27,935.50	57,939.33	72,244.82
6	Tax Expenses					
	a) Current tax	4,296.76	3,715.23	5,148.01	14,462.56	15,763.03
	b) Deferred tax	150.88	66.59	341.02	433.75	671.91
	c) Prior year tax	(217.23)	-	-	(217.23)	-
7	Net Profit/ (Loss) for the period/year(5-6)	13,016.18	10,946.62	22,446.47	43,260.25	55,809.88
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	41.29	(25.48)	(18.06)	(35.16)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(10.39)	6.41	4.55	8.85	25.66
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	30.90	(19.07)	(13.51)	(26.31)	(76.29)
9	Total Comprehensive Income for the period (7+8)	13,047.08	10,927.55	22,432.96	43,233.94	55,733.59
10	Paid-up equity share capital	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity				1,72,392.41	1,49,523.67
12	Earning Per Share (EPS)-Face value of Rs.1/- each)					
	a) Basic	5.11	4.30	8.82	16.99	21.92
	b) Diluted	5.11	4.30	8.82	16.99	21.92
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)



PART - II		CONSOLIDATED				
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended	
		31-03-2023	31-12-2022	31-03-2022	31-03-2023	31-03-2022
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	AUDITED
1	Income					
	Revenue from operations	36,935.62	35,377.17	36,384.72	1,34,032.88	1,32,022.21
	Other Income	1,139.95	1,301.12	1,687.12	4,636.38	9,238.03
	Total income	38,075.57	36,678.29	38,071.84	1,38,669.26	1,41,260.24
2	Expenses					
	a) Cost of materials consumed	9,555.70	13,603.62	13,027.81	43,007.88	45,945.64
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,087.69	(2,639.91)	(1,994.03)	(2,094.42)	(6,035.21)
	c) Manufacturing Expenses	4,046.62	4,736.40	4,434.34	17,628.79	17,318.86
	d) Employee benefits expense	2,560.21	2,967.54	3,112.20	11,051.09	10,048.39
	e) R & D expense	200.90	226.98	214.42	858.57	1,035.45
	f) Finance costs	230.86	138.27	218.87	543.63	623.10
	g) Depreciation and amortisation expense	1,195.83	1,223.90	1,042.08	4,773.24	3,909.71
	h) Other Expenses	1,576.67	1,813.06	1,887.94	6,927.50	5,766.55
	Total expenses	21,454.48	22,069.86	21,943.63	82,696.28	78,612.49
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	16,621.09	14,608.43	16,128.21	55,972.98	62,647.75
4	Add : Share of profit/(Loss) of Associates.	-	-	-	-	4,111.23
5	Profit before exceptional items , Tax (3+4)	16,621.09	14,608.43	16,128.21	55,972.98	66,758.98
6	Exceptional Items	-	-	-	-	-
7	Profit before Tax (5-6)	16,621.09	14,608.43	16,128.21	55,972.98	66,758.98
8	Tax Expenses					
	a) Current tax	4,290.32	3,769.77	5,964.54	14,627.43	19,040.47
	b) Deferred tax	150.87	66.60	996.87	433.75	2,338.02
	c) Prior year tax	(217.23)	-	-	(217.23)	-
9	Net Profit/ (Loss) for the period/year(7-8)	12,397.13	10,772.06	9,166.80	41,129.03	45,380.49
10	Other Comprehensive Income					
10.a	(i) Items that will not be reclassified to profit or loss	49.28	(25.60)	(18.06)	(27.49)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(10.39)	6.41	4.55	8.85	25.66
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	38.89	(19.19)	(13.51)	(18.64)	(76.29)
11	Total Comprehensive Income for the period (9 + 10)	12,436.02	10,752.87	9,153.29	41,110.39	45,304.20
12	Paid-up equity share capital	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
13	Other Equity				1,70,972.78	1,50,172.39
14	Earning Per Share (EPS)- (Face value of Rs. 1/- each)					
	a) Basic -	4.87	4.23	3.60	16.16	17.83
	b) Diluted	4.87	4.23	3.60	16.16	17.83
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)



- Notes**
- 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 25th May, 2023. The results for the year ended 31st March, 2023 have been audited and for the quarter ended 31st March, 2023 has been reviewed by our statutory auditors. The statutory auditors of the company have expressed an unmodified opinion on the financials statements for the year ended 31st March, 2023 and issued an unmodified conclusion in respect of limited review for the quarter ended 31st March, 2023
 - 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
 - 3) The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, Inc., USA & Casper Pharma Pvt Ltd, (wef from 22nd April '2022).
 - 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
 - 5) The other Income (Standalone figures for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q2 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs (Q4) pertaining to Gain on Investments on part disinvestment of Capital from our Wholly Owned Subsidiary, Suven pharma, Inc. The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such dividend by our wholly owned subsidiary.
 - 6) The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to \$35.00 Mn) in M/s Rising pharma Holdings, Inc., USA on 13th Dec, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of US \$41.555 Mn and a stake valued at US \$15.803 Mn in Raisin Aggregators, L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021
 - 7) Post approval of the Board in the meeting held on 5th April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd, (SEZ company) engaged in formulations business for US \$20.50 Mn and has become a Wholly Owned Subsidiary of the Company w.e.f 22 nd April 2022. Subsequently subscribed the right issue in the ratio of 4:1 on 22/06/2022 of 52,16,156 shares of face value of Rs.10.00 with a premium of Rs.70.00 per share for Rs.4172.92 Lacs.
 - 8) The Promoter Group, Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust), informed the Company that they executed a Share Purchase Agreement to sell 12,75,37,043 Equity shares representing 50.10% of the Voting share capital to Berhyanda Limited company on 26th December 2022.
 - 9) The corresponding previous period figures have been regrouped/reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD



VENKATESWARLU JASTI
Managing Director
DIN: 00278028

Place : Hyderabad
Date : 25 th May ' 2023




Statement of Assets & Liabilities



Rs.in Lakhs



Particulars	Standalone as at		Consolidated as at	
	31-03-2023	31-03-2022	31-03-2023	31-03-2022
	Audited	Audited	Audited	Audited
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	50,900.87	53,055.18	58,418.83	53,055.18
(b) Capital Work-in-Progress	16,481.46	2,999.38	16,508.86	2,999.38
(c) Other Intangible Assets	193.20	223.64	6,219.02	223.64
(e) Right of use of assets	108.67	140.56	1,694.80	140.56
(f) Financial Assets				
I. Investments	31,721.01	11,867.29	11,709.66	11,709.67
II. Loans	2.25	6.95	2.25	6.95
III. Other Financial Assets	591.19	539.21	591.19	1,269.59
(g) Other non current assets	322.75	760.56	325.19	760.56
Total Non-Current assets	1,00,321.40	69,592.77	95,469.80	70,165.53
2 Current assets				
(a) Inventories	31,146.62	28,341.73	31,281.05	28,341.73
(b) Financial Assets				
I. Investments	39,284.94	48,122.24	41,893.50	48,122.24
II. Trade Receivables	10,966.45	23,637.23	11,093.93	23,637.23
III. Cash and Cash equivalents	4,302.13	3,021.05	6,480.28	4,456.38
IV. Bank balances otherthan (III) above	321.13	274.20	321.12	274.20
V. Loans	19.29	18.63	19.29	18.63
VI. Other financial Assets	28.17	-	28.17	-
(d) Other current assets	9,442.91	7,480.94	9,987.24	7,942.79
Total Current assets	95,511.64	1,10,896.02	1,01,104.58	1,12,793.20
TOTAL - ASSETS	1,95,833.04	1,80,488.79	1,96,574.38	1,82,958.73
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	2,545.65	2,545.65	2,545.65	2,545.65
(b) Other Equity	1,72,392.41	1,49,523.67	1,70,972.78	1,50,172.39
Equity attributable to owners of the company	1,74,938.06	1,52,069.32	1,73,518.43	1,52,718.04
2 LIABILITIES				
(a) Financial Liabilities				
I. Lease Liability	69.98	46.29	69.98	46.29
II. Borrowings	456.42	2,844.04	456.42	2,844.04
(b) Provisions	786.52	889.45	829.51	889.45
(c) Deferred tax Liabilities (net)	4,164.45	3,739.55	5,823.46	5,431.51
Total non-current liabilities	5,477.37	7,519.33	7,179.37	9,211.29
Current liabilities				
(a) Financial Liabilities				
I. Lease Liability	47.90	109.09	47.90	109.09
II. Borrowings	6,459.78	6,713.31	6,459.78	6,713.31
III. Trade payables				
a) To Micro & Small Enterprises	1,382.03	200.20	1,383.01	200.20
b) Other than Micro & Small Enterprises	4,814.35	10,389.85	5,133.42	10,389.85
IV. Other Financial Liabilities	2,015.35	2,126.01	2,133.20	2,255.27
(b) Current Tax liabilities (Net)	30.41	364.22	29.39	364.22
(c) Provisions	385.68	407.53	394.61	407.53
(d) Other Current liabilities	282.11	589.93	295.27	589.93
Total Liabilities	20,894.98	28,419.47	23,055.95	30,240.69
TOTAL - EQUITY AND LIABILITIES	1,95,833.04	1,80,488.79	1,96,574.38	1,82,958.73

For Suvem pharmaceuticals Ltd

 Place : Hyderabad
 Date: 25th May, 2023


 Venkateswarlu Jasti
 Managing Director

SUVEN PHARMACEUTICALS LIMITED			
Standalone Statement of Cash flows for the year ended 31st March , 2023			
(All amounts in Indian Rupees in Lakhs, unless otherwise stated)			
Particulars		For the year ended March 31, 2023	For the year ended March 31, 2022
A. Cash flow from operating activities			
Profit before tax		57939.33	72,244.82
Adjustments :			
Depreciation and amortisation expense		4190.40	3,825.50
Interest Income		(572.00)	(6.86)
Finance Cost		539.17	623.10
Gain on sale of Current Investment		(1421.05)	(820.31)
Dividend received from Subsidiary		0.00	(15,081.85)
Effects of foreign exchange rates (Unrealized)		95.43	442.01
Loss/(Profit) on disposal of Property,plant & equipment		0.65	(0.06)
Operating profit before working capital changes		60771.93	61226.35
Adjustments for (Increase)/decrease in operating assets			
Trade Receivables		12574.00	(13,608.80)
Inventories		(2804.89)	(8,233.69)
Other non current assets		31.89	26.97
Other current assets		(1962.11)	(621.56)
Adjustments for Increase/(decrease) in operating liabilities			
Trade Payables		(4392.64)	2,320.35
Long term provisions		(102.93)	224.85
Short term provision		(57.01)	44.86
Other financial liabilities		(754.26)	420.66
Other current liabilities		(307.82)	363.60
Cash generated from operating activities		62996.16	42163.59
Income taxes paid (net of refunds)		(14579.14)	(15,174.14)
Net Cash flows from operating activities	(A)	48417.02	26989.45
B. Cash flow from Investing activities			
Payments for Purchase of property, plant and equipment		(14460.65)	(7,518.67)
Proceeds from sale of Property, plant & equipment		7.20	0.06
Investment in Subsidiaries		(19853.72)	12,697.44
Dividend received from Subsidiary		0.00	15,081.85
Interest received from FD and debentures		572.00	6.86
Fixed deposits/margin money-placed/matured		(80.01)	(44.03)
Sale/(purchase) of mutual funds		10258.35	(29,242.55)
Bank balances not considered as cash and cash equivalents		(0.44)	(10.47)
Net cash flow from /(used in) investing activities	(B)	(23557.27)	(9,029.51)
C. Cash flows from financing activities			
(Repayment)/Proceeds from long term borrowings		(2375.75)	(960.48)
(Repayment)/Proceeds from short term borrowings		(261.05)	(3,856.56)
Changes in Lease Liabilities		(37.50)	(25.33)
Finance Cost		(539.17)	(623.10)
Dividends paid to equity holders (including dividend distribution tax)		(20365.20)	(10,182.60)
Net cash flow from /(used In) financing activities	(C)	(23578.67)	(15,648.07)
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	1281.08	2311.87
Cash and cash equivalents as at the beginning of the year		3021.05	709.14
Effect of exchange differences on restatement on foreign currency cash & cash equivalents		0.00	0.04
Cash and cash equivalents at the end of the year		4302.13	3021.05
For Suven Pharmaceuticals Ltd			
 Venkateswarlu Jasti Managing Director DIN: 00278028			
			
Place : Hyderabad			
Date : 25th May 2023			

SUVEN PHARMACEUTICALS LIMITED			
Consolidated Statement of Cash flows for the year ended 31st March, 2023			
(All amounts in Indian Rupees in Lakhs, unless otherwise stated)			
Particulars		For the year ended March 31, 2023	For the year ended March 31, 2022
A. Cash flow from operating activities			
Profit before tax		55972.98	66,758.98
Adjustments :			
Depreciation and amortisation expense		4645.99	3,825.50
Interest Income		(583.16)	(6.86)
Finance Cost		543.63	623.10
Gain on sale of Current Investment		(1568.70)	(820.31)
Effects of foreign exchange rates (unrealized)		95.42	442.01
Loss/(Profit) on disposal of property, plant & equipment		0.65	(0.06)
Operating profit before working capital changes		59106.81	70822.36
Adjustments for (Increase)/decrease in operating assets			
Trade receivables		12446.52	(13,608.80)
Inventories		(2939.32)	(8,233.69)
Other non current assets		(1554.24)	26.97
Other current assets		(2044.58)	(1,083.41)
Adjustments for Increase/(decrease) in operating liabilities			
Trade payables		(4072.59)	2,320.35
Long term provisions		(59.94)	224.85
Short term provision		(40.41)	44.86
Other financial liabilities		(877.21)	548.66
Other current liabilities		(294.66)	363.60
Cash generated from operating activities		59670.38	51425.75
Income taxes paid (net of refunds)		(14579.14)	(18,425.73)
Net Cash flows from operating activities	(A)	45091.24	33000.02
B. Cash flow from Investing activities			
Purchase of property, plant and equipment		(28577.15)	(7,518.67)
Proceeds from sale of property, plant & equipment		7.20	0.06
Investment in subsidiaries		0.00	24,409.74
Interest received from FD and debentures		583.16	6.86
Foreign currency translation reserve		55.19	(484.39)
Fixed deposits/margin money-placed/matured		650.37	(774.41)
Sale/(purchase) of mutual funds		7797.44	(29,242.55)
Bank balances not considered as cash and cash equivalents		(0.44)	(10.47)
Net cash flow from /(used in) investing activities	(B)	(19484.22)	(13613.83)
C. Cash flows from financing activities			
(Repayment)/proceeds from long term borrowings		(2375.75)	(960.48)
(Repayment)/proceeds from short term borrowings		(261.05)	(3,856.56)
Changes in Lease Liabilities		(37.49)	(25.33)
Finance costs		(543.63)	(623.10)
Dividends paid to equity holders		(20365.20)	(10,182.60)
Net cash flow from /(used In) financing activities	(C)	(23583.12)	(15648.07)
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	2023.90	3738.12
Cash and cash equivalents as at the beginning of the year		4456.38	718.22
Effect of exchange differences on restatement on foreign currency cash & cash equivalents		0.00	0.04
Cash and cash equivalents at the end of the year		6480.28	4456.38
For Suven Pharmaceuticals Ltd  Venkateswarlu Jasti Managing Director DIN: 00278028			
			
Place : Hyderabad Date : 25th May 2023			



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

**TO
THE BOARD OF DIRECTORS OF
SUVEN PHARMACEUTICALS LIMITED**

Opinion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2023 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2023 (refer 'Other Matters' section below) which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2023 ("the Statement") of SUVEN PHARMACEUTICALS LIMITED ("the Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").


(a) Opinion on Annual Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2023:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive Income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2023

With respect to the Standalone Financial Results for the quarter ended March 31, 2023, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2023, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



25/05/2023

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2023

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under Section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those Standards are further described in paragraph (a) of Auditor’s Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“the ICAI”) together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2023 under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management’s Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company’s Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2023 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2023 that give a true and fair view of the net profit and other comprehensive Income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and Fairview and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company’s ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.



25/05/2023

Auditor's Responsibilities for

(a) Audit of the Standalone Financial Results for the year ended March 31, 2023

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2023 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained upto the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



25/05/2023

- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2023

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2023 in accordance with the Standard on Review Engagements (“SRE”) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- These standalone financial results incorporate the relevant returns of foreign branch audited by the other auditors specifically appointed for this purpose, whose financial information

25/05/2023



reflect total assets of Rs.56.41 lakhs as at March 31, 2023 and total revenues of Rs. NIL for the year ended March 31, 2023, total net loss of Rs. (1,036.35) lakhs for year ended March 31, 2023

- Attention is drawn to the Statement which states that the Standalone Financial Results includes the results for the Quarter ended March 31, 2023 being the balancing figure between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the current financial year Our report is not modified in respect of this matter.
- Attention is drawn to the Statement, the figures for the corresponding quarter ended March 31, 2022 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2021. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2022. our report is not modified in respect of this matter.

For **KARVY & CO,**
Chartered Accountants
(Firm Registration No. 001757S)



AJAYKUMAR KOSARAJU
Partner
Membership No. 021989
UDIN: 23021989BGRFLJ4182



Place: Hyderabad
Date : 25th May, 2023

25/05/2023



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

**TO
THE BOARD OF DIRECTORS OF
SUVEN PHARMACEUTICALS LIMITED**

KARVY & CO
CHARTERED ACCOUNTANTS

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2023 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2023 (refer "Other Matters" section below), which were subject to limited review by us, both included in the accompanying "Consolidated Financial Results for the quarter and year ended March 31, 2023" of **SUVEN PHARMACEUTICALS LIMITED** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group") and its share of the net profit after tax and total comprehensive income of its associate company for the quarter and year ended March 31, 2023, (the "Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on financial information of the subsidiary and associate referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2023:

(i) Includes the results of the following entities:

Name of the Company	Country	Relationship
Casper Pharma Pvt Ltd	INDIA	Wholly Owned Subsidiary
SUVEN PHARMA INC	USA	Wholly Owned Subsidiary

(ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group and its associate for the year ended March 31, 2023.



25/05/2023

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2023

With respect to the Consolidated Financial Results for the quarter ended March 31, 2023, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the audit reports for the year ended March 31, 2023 of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2023, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2023


We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group, its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2023 under the provisions of the Act and the Rules there under and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2023, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2023 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associate in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group and its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group, its associate and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and

25/05/2023



the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and its associate are responsible for overseeing the financial reporting process of the Group and associate.

Auditor's Responsibilities for


(a) Audit of the Consolidated Financial Results for the year ended March 31, 2023

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2023 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing

25/05/2023



Regulations.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Information of the entities within the Group and its associate to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



25/05/2023

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2023

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2023 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

As part of annual audit we also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- Attention is drawn to the Statement which states that the Consolidated Financial Results includes the results for the Quarter ended March 31, 2023 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year .Our report is not modified in respect of this matter.
- Attention is drawn to the Statement, the figures for the corresponding quarter ended March 31, 2022 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2021. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2022. Our report is not modified in respect of this matter.
- We did not audit the financial information of the two subsidiaries included in the consolidated financial results, whose financial information reflect total assets of Rs.741.72 lakhs as at March 31, 2023 and total revenues of Rs.561.12 Lakhs and Rs.1,206.07 Lakhs for the quarter and year ended March 31, 2023 respectively, total Net Loss after tax of Rs.(619.05)Lakhs and Rs.(2,131.22)Lakhs for the quarter and year ended March 31, 2023 respectively and total Comprehensive Loss of Rs.(611.06) Lakhs and Rs.(2,123.55) Lakhs for the quarter and year ended March 31, 2023 respectively and net cash inflows of Rs.742.81 Lakhs for the year ended March 31, 2023, as considered in the Statement. These financial information have been audited, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.




25/05/2023

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For **KARVY & CO,**
Chartered Accountants
(Firm Registration No. 001757S)

AJAYKUMAR KOSARAJU
Partner
Membership No. 021989
UDIN: 23021989BGRFLK2807



Place: Hyderabad
Date: 25th May, 2023

25/05/2023

CSD/SE/BM/2023-24
May 25, 2023

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

.....

We hereby declare that the Statutory Auditors of the Company, M/s. Karvy & Co., (FRN: 001757S) Chartered Accountants have issued an Audit Reports with unmodified opinion on audited financial results of the company (Standalone and Consolidated) for the year ended 31st March, 2023.

We request you to take this document on your record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**


Venkateswarlu Jasti
Managing Director

Suven Pharmaceuticals Limited



SUVEN PHARMA

Earnings Presentation
Q4 & FY23





Risk Statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Seven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Seven may not undertake to update any forward-looking statements that may be made from time to time.



4

**Operation &
Financial
Performance
Q4FY23**




14

**Company
Background**

Table of Contents




Operation & Financial Performance Q4FY23

Businesswise data



Note: Figures in INR Crore

Businesswise data





Note: Figures in INR Crore

Financial Snapshot



Q4FY23*

FY23



Growth in
Revenue



Growth in
EBITDA



Growth in
PAT




*Compared to previous quarter

Key Ratios



Q4FY23*

FY23



Growth in
EBIT



EBITDA to
Income







PAT to
Income







*Compared to previous quarter

Financials Q4FY23





Note: Figures in INR Million

Financials FY23





Note: Figures in INR Million

Financials Q4FY23



Financials FY23



Financial Snapshot – Q4 and FY23

Financial Snapshot


INR (Millions, except ratios and EPS)

	Quarter ended			Year ended	
	31-Mar-23	31-Dec-22	31-Mar-22	31-Mar-23	31-Mar-22
Revenue from operations	3,643.90	3,484.89	3,638.47	13,300.80	13,202.22
Other Income	107.55	125.11	1,343.96	445.52	1,877.88
Total income	3,751.45	3,610.00	4,982.43	13,746.32	15,080.10
EBITDA	1,853.83	1,595.78	2,919.65	6,276.30	7,677.76
EBITDA Margin	49.42%	44.20%	58.60%	45.66%	50.91%
EBIT	1,747.55	1,486.64	2,815.44	5,847.85	7,286.79
EBIT Margin	46.58%	41.18%	56.51%	42.54%	48.32%
Finance costs	22.90	13.79	21.89	53.92	62.31
Depreciation	106.27	109.14	104.21	428.45	390.97
Taxes	423.04	378.18	548.90	1,467.91	1,643.49
Taxes to PBT	24.53%	25.68%	19.65%	25.34%	22.75%
PAT (Standalone)	1,301.62	1,094.66	2,244.65	4,326.03	5,580.99
PAT Margin (Standalone)	34.70%	30.32%	45.05%	31.47%	37.01%
Associate Company	-	-	-	-	411.12
PAT (Consolidated)	1,239.71	1,077.21	916.68	4,112.90	4,538.05
PAT Margin (Consolidated)	33.05%	29.84%	18.40%	29.92%	30.09%
EPS (Standalone)	5.11	4.30	8.82	16.99	21.92
EPS (Consolidated)	4.87	4.23	3.60	16.16	17.83
Paid up share capital (Re.1/sh)	254.56	254.57	254.57	254.56	254.56

All figures are in INR Million, other than ratios and EPS

Company Background

Business Model



Brief Profile

BUSINESS OVERVIEW

- Integrated CDMO company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing.

KEY STRENGTHS

- Preferred global outsourcing partner with capabilities across the entire CDMO value chain.
- Strong chemistry skills.

FINANCIAL OVERVIEW

- Standalone Revenues, EBIT and PAT of Rs 13476 Mn, Rs 5847 Mn and Rs 4326 Mn in FY23.
- Adjusted PBT for for FY23 stood at Rs. 5793.93 Mn compared to FY22 of Rs. 5716.29 Mn. The adjustment is related to inclusion of pre-tax dividend of Rs. 1508.19 Mn in other income.

Overview

Suven is an integrated Contract Development and Manufacturing Operations company

Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations.

Since our founding in 1989 (pre-demerger), Suven has established its core competency in cyanation and heterocyclic chemistry, including pyrimidines, quinolones, thiazoles, and imidazoles, in addition to demonstrating our proficiency in Carbohydrate and Chiral chemistry including tetrahydrofurans, amino acids and sulfoxides from gram to multi-ton scale.

Suven effectively uses its expanding infrastructure and ability to collaborate, from route scouting and development through commercial manufacture, to provide a consistent and reliable partner throughout a product's life cycle.

Suven is dedicated to going beyond commitment and delivering R&D and Manufacturing solutions, with flexibility, quality, speed, and cost effectiveness.


Our Focus

A full-fledged bio-pharmaceutical solutions provider for global pharmaceutical companies




**NCE based
CDMO**

Financial Approach




Business Drivers

Industry Relationship




Business Drivers

Execution Capabilities



Multi Location Facilities

Vizag, Andhra Pradesh, India



- 307 KL reactor volume
- 3KL to 12KL Reactors
- GL/SS (45No's)
- API's/Advanced Intermediate's/CMO

**Pashamylaram, Telangana, India
API & Formulation Facility**



- 120 kL reaction volume
- 50L – 6000 L GL/SS (45)
- API Manufacturing
- Formulation R&D


**Banjara Hills, Hyderabad, India
Corporate Office**



- Process Research
- Discovery R&D, Analytical R&D
- Killo lab, 30L CM Reactors (32)
- 50L – 4000 L GL/SS

**Jeedimetla, Telangana, India
R&D-Pilot Plant**

**Suryapet, Telangana, India
Intermediate Mfg. Facility**



- Business Development
- Project Management
- Intellectual Property Management

**USA, New Jersey
Business Office**

- 300 CM reactors (93)
- 500L to 10 KL GL/SS
- GMP Intermediates

Contact

Suven Pharmaceuticals Ltd

8-2-334, SDE Serene Chambers,
3rd Floor, Road No. 5, Avenue - 7, Banjara
Hills, Hyderabad-500 034, Telangana, INDIA.

+91-40-2354-9414 /1142 /3311

**For queries and requests, please
contact:**

Sunder Venkatraman
Suven Pharmaceuticals Ltd

Tel: +91 939 248 3011

Email: info@suvenpharm.com

For more info: www.suvenpharm.com

Gavin Desa / Rishab Barar
CDR - India

Tel: +91 22 6645 1237 / 1235

Email: gavin@cdr-india.com

rishab@cdr-india.com